Healthcare Scares to Drive the Global Blood Banking and Blood Products Market, According to New Report by Global Industry Analysts, Inc.

GIA announces the release of a comprehensive global report on Blood Banking and Blood Products markets. Global market for Blood Banking and Blood Products is projected to reach US$43 billion by 2018, driven by health scares and regulatory requirements. Worldwide market for Blood Banking and Blood Products is exhibiting a healthy trend, thanks to an aging population, and a steep increase in healthcare expenditures.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Blood Banking and Blood Products: A Global Strategic Business Report

San Jose, California (PRWEB) October 12, 2012

Follow us on LinkedIn – Though temporarily impacted by the economic recession, new infections continue to take a toll on population in developing nations, fueling demand for blood banking and blood products. Regulatory and healthcare bodies across the world, in a bid to serve these people, are adopting stringent policies relating to blood safety. As an extension to this, manufacturers all over the world are developing improved, safer, and advanced blood banking technologies for the collection, processing and delivery of blood products.

The worldwide production of blood plasma products is considerably lesser than demand, which for some products is rising at a rate of 14.6% each year. Fractionating facilities are also decreasing in number, increasing the burden on the remaining sources. The industry is rendered vulnerable to economic fluctuations and export regulations. Developing countries rely on imports from other countries as they face immense hardship in fulfilling domestic requirements. However, these countries cannot afford the high costs. Excess production is either absent or very less in developed nations, to cater to the requirements of countries in need. Even if excess plasma products are available, they are highly expensive in most cases. Amid the present situation, the WHO asserts that self-sufficiency is the only solution for developing countries and can be achieved by locally situated manufacturing plants with capabilities to produce plasma products of superior quality. Consequently, requirements of the domestic population can be fulfilled. Good quality supply is advantageous in the long run as it increases the number of treated individuals, lowers the incidence of infections and shortens in-patient stay. Moreover, as the products are sourced and distributed locally, donor-patient traceability is relatively easy.

Blood Banking and Blood Products market is largely concentrated in developed countries. Of the entire global market for therapeutic plasma products, the Asia-Pacific region accounts for a significant portion of sales. However, the US and European markets are the first preferences for plasma fractionators. The Asian market is provided with products from surplus production, causing fluctuations in supply and explosive costs. Regional markets, particularly India and China, are controlled by five leading companies, which witnessed a flurry of consolidation activity as well as reorganization over the past few years. Nonetheless, the region lacks a global commercial plasma fractionation plant and the process of manufacturing plasma products through fractionation is rigid, capital intensive, and involves high costs.

Although blood and blood products provided by blood banks are free from viruses, bacteria, and other disease causing microorganisms, safety has become the main issue the world over. Risks involved in blood transfusion have also become a major issue in the blood banks and blood products industry. In such a situation, the proliferation of new diseases and viruses are posing to be a threat to blood transfusion. While infections proliferate through transfusion of infected blood, other problematic reactions such as circulatory overhead, Thrombophlebitis, and Graft Versus Host Disease, do occur due to blood transfusion, which is highly unacceptable.

As stated by the new market research report on Blood Banking and Blood Products, Europe represents the largest market worldwide. Asia-Pacific region offers the highest growth potential owing to the large untapped market. Blood Components and Plasma Products represent the largest product group for Blood Banking and Blood Products while Plasma Fractions segment offers the highest growth potential.

The marketplace for plasma derived products is dotted with a small number of players having global reach, and entry into the market is hard. The plasma derivatives market underwent a series of consolidations in the last twenty years lowering the player count from more than twenty to five. In 2011, Grifols took over Talecris, and players holding the majority share reduced to four. The US leads in the provision of sourced plasma and is also the biggest plasma products market in the world.

Major players in the global marketplace include Beckman Coulter, Inc., Becton Dickinson and Company, BioMerieux SA, CSL Behring LLC, Daxor Corporation, Fenwal Inc., Gen-Probe, Inc., Haemonetics Corporation, Hemagen Diagnostics Inc., Immucor Inc., Kawasumi Laboratories, Inc., Novartis Vaccines and Diagnostics, Inc., Terumo Corp., Terumo BCT Inc., ThermoGenesis Corp., Velico Medical, Inc., Baxter International Inc., Beijing Tiantan Biological Products Co., Ltd., Bharat Serums and Vaccines Ltd., Bio Products Laboratory Ltd., Biotest AG, CSL Limited, Grifols, S.A., Guizhou Taibang Biological Products Co., Ltd., Huanlan Biological Engineering Inc., Kedrion S.p.A., Laboratoire Français du Fractionnement et des Biotechnologies, Octapharma AG, OMRIX Biopharmaceuticals Ltd., Shanghai RAAS Blood Products Co., Ltd., Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., and Sanquin.

The research report titled "Blood Banking and Blood Products: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of market trends, issues, drivers, company profiles, product approvals, mergers, acquisitions and other strategic industry activities. The report provides market estimates and projections for Blood Banking and Blood Products (in US$ million) by Blood Components and Plasma Products (Whole Blood & Cellular Components, and Plasma Fractions); and Equipment, Blood Tests and Other Consumables. Geographic markets analyzed include the United States, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia, and Rest of Europe), Asia-Pacific, Latin America, and Rest of World.

For more details about this comprehensive market research report, please visit –
http://www.strategyr.com/Blood_Banking_and_Blood_Products_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/

###


Contact

Attachments